Blog and Whitepapers
Recon takes an analytical look behind select developments in healthcare
- By Marc Herant
Preempting severe genetic disease
Around 2% of births come with a genetic disease, often with devastating impact. While some appear de novo (either from germplasm dominant mutations or from chromosomal accidents), a fraction are inherited (from the mother if X-linked, from both parents if autosomal recessive) and can be predicted (before conception) by gene sequencing parents. In a fascinating stu…
Keep up with the Recon Strategy Insights
Get an email each time Recon takes an analytical look behind select developments in healthcare.
- By Marc Herant
Hydroxychloroquine does not seem to help much in Covid-19 (with caveat)
There has been significant attention to the use of the antimalarial hydroxychloroquine in Covid-19, but data on impact has been …
- By Nikhil Bhojwani
Preamble
A recent post from Recon Strategy outlined the longer-term strategic implications of Covid-19 on 12 healthcare sectors. This post highlights the opportunity to redeploy corporate strategy ass…
- By Nikhil Bhojwani
Even as our priority today is dealing with the Covid crisis, healthcare organizations would do well to start thinking about the longer-term implications for their strategies. In some instances the mar…
- By Marc Herant
A first Covid-19 interventional study – unfortunately negative
The first of what promises to be a series of many interventional studies for acute Covid-19 disease to appear in the Journal. Lopinavir i…
- By Marc Herant
Keeping up with COVID-19
It’s not easy for a refereed weekly print periodical to keep up with an epidemic that evolves on a daily basis, but the NEJM is doing its best and all articles are free on-lin…
- By Marc Herant
The loneliness of the patent-less drug
Colchicine is a very old drug commonly used in gout with an anti-inflammatory mechanism of action that is not well defined. It is a generic (although in the US, …
- By Marc Herant
A triumph for cystic fibrosis patients (and for Vertex)
Phase 3 confirmation that the benefits seen in early trials from triple-combination therapy of elexacaftor, tezacaftor, and ivacaftor, are susta…
- By Marc Herant
Genomic applications and scalability
Two very different papers about applications of genomics, one for a very common clinical scenario, the other for an ultra-rare disease.
It is well known that while…
- By Marc Herant
Best care vs. good care
In wealthy countries, the recommended standard of care can often lead to complex medication regimens requiring frequent follow-ups: this can be very challenging for people who …
- By Tory Wolff
Last month, Warburg Pincus closed on previously announced plans to acquire a major multi-specialty practice in northern New Jersey (Summit) and combine it with an urgent care network centered in the N…
- By Marc Herant
Is the lack of new (non-viral) antibiotics a market failure?
A lament about the lack of success in getting the biopharma industry to invest sustainably in the development of new antibiotics against h…
- By Tory Wolff
MSFT’s pathbreaking alliances in healthcare services are impressive and well designed to grow adoption of their Azure cloud over the medium term. But if MSFT wants to be at the forefront of change an…